Colorectal Cancer

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

John L. Marshall, MD, discusses ​sequencing challenges in colorectal cancer.

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Nilofer S​aba Azad, MD, discusses remaining challenges in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

The combination of onvansertib plus with 5-fluorouracil, FOLFIRI, and bevacizumab was shown to have preliminary efficacy with acceptable safety when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Elena M. Stoffel, MD, MPH, discusses the importance of genetic testing in detecting Lynch syndrome and other hereditary syndromes associated with risk of colorectal cancer and other diseases.

Richard D. Kim, MD, discusses the potential of regorafenib plus nivolumab in patients with advanced colorectal cancer and the need for biomarkers to predict response to the regimen.

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Caroline Farrington, PhD, ​discusses the importance of patient advocacy in colorectal cancer.

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.